The Respiratory Evaluation Sciences Program (RESP) is a comprehensive epidemiology, health outcomes, and health economics program focused on chronic respiratory diseases, namely asthma and chronic obstructive pulmonary disease (COPD).
Research
We are a leading group in using clinical and ‘big’ data, prediction modeling, and computer simulation (disease modeling) techniques to evaluate the real-world effectiveness of health technologies and their ‘value for money’ potential.
The RESP group is deeply involved in Health Technology Assessment (HTA) through its collaboration with Centre for Clinical Epidemiology and Evaluation at VCHRI.
Care
The RESP program has been influential in shaping best practice standards in asthma and COPD management. This is exemplified in the involvement of co-PI Mohsen Sadatsafavi in two American Thoracic Society (ATS) guideline development committees: Pharmacological Management of COPD and Observational Research Assessing Causal Effect.
Our team is currently evaluating digital health technologies in care of COPD patients in implementation-oriented designs that can be incorporated into routine care.
Research
We are a leading group in using clinical and ‘big’ data, prediction modeling, and computer simulation (disease modeling) techniques to evaluate the real-world effectiveness of health technologies and their ‘value for money’ potential.
The RESP group is deeply involved in Health Technology Assessment (HTA) through its collaboration with Centre for Clinical Epidemiology and Evaluation at VCHRI.
Care
The RESP program has been influential in shaping best practice standards in asthma and COPD management. This is exemplified in the involvement of co-PI Mohsen Sadatsafavi in two American Thoracic Society (ATS) guideline development committees: Pharmacological Management of COPD and Observational Research Assessing Causal Effect.
Our team is currently evaluating digital health technologies in care of COPD patients in implementation-oriented designs that can be incorporated into routine care.